Published in J Nucl Med on January 01, 2005
Clinical experience with alpha-particle emitting 211At: treatment of recurrent brain tumor patients with 211At-labeled chimeric antitenascin monoclonal antibody 81C6. J Nucl Med (2007) 1.57
Targeted alpha-particle radiotherapy with 211At-labeled monoclonal antibodies. Nucl Med Biol (2007) 1.25
A semiempirical model of tumor pretargeting. Bioconjug Chem (2008) 1.16
Cancer radioimmunotherapy. Immunotherapy (2011) 1.10
Biodistributions, myelosuppression, and toxicities in mice treated with an anti-CD45 antibody labeled with the alpha-emitting radionuclides bismuth-213 or astatine-211. Cancer Res (2009) 1.08
Radioimmunotherapy of human tumours. Nat Rev Cancer (2015) 1.07
Auger radiation targeted into DNA: a therapy perspective. Eur J Nucl Med Mol Imaging (2006) 1.04
Use of antibodies and immunoconjugates for the therapy of more accessible cancers. Adv Drug Deliv Rev (2008) 1.00
Gold coated lanthanide phosphate nanoparticles for targeted alpha generator radiotherapy. PLoS One (2013) 1.00
Effective treatment of established human breast tumor xenografts in immunodeficient mice with a single dose of the alpha-emitting radioisotope astatine-211 conjugated to anti-HER2/neu diabodies. Clin Cancer Res (2008) 0.99
Radionuclide carriers for targeting of cancer. Int J Nanomedicine (2008) 0.94
ARRONAX, a high-energy and high-intensity cyclotron for nuclear medicine. Eur J Nucl Med Mol Imaging (2008) 0.92
Detection of hypoxia in microscopic tumors using 131I-labeled iodo-azomycin galactopyranoside (131I-IAZGP) digital autoradiography. Eur J Nucl Med Mol Imaging (2009) 0.89
Anti-CD45 pretargeted radioimmunotherapy using bismuth-213: high rates of complete remission and long-term survival in a mouse myeloid leukemia xenograft model. Blood (2011) 0.89
Effective treatment of a murine model of adult T-cell leukemia using 211At-7G7/B6 and its combination with unmodified anti-Tac (daclizumab) directed toward CD25. Blood (2006) 0.87
Reagents for astatination of biomolecules. 3. Comparison of closo-decaborate(2-) and closo-dodecaborate(2-) moieties as reactive groups for labeling with astatine-211. Bioconjug Chem (2009) 0.87
Targeted alpha therapy using short-lived alpha-particles and the promise of nanobodies as targeting vehicle. Expert Opin Biol Ther (2016) 0.85
Inorganic chemistry in nuclear imaging and radiotherapy: current and future directions. Radiochim Acta (2012) 0.84
In vivo molecular targeted radiotherapy. Biomed Imaging Interv J (2005) 0.83
(2S)-2-(3-(1-Carboxy-5-(4-211At-Astatobenzamido)Pentyl)Ureido)-Pentanedioic Acid for PSMA-Targeted α-Particle Radiopharmaceutical Therapy. J Nucl Med (2016) 0.83
Targeted α-particle therapy of bone metastases in prostate cancer. Clin Nucl Med (2013) 0.82
Anti-CD45 radioimmunotherapy using (211)At with bone marrow transplantation prolongs survival in a disseminated murine leukemia model. Blood (2013) 0.81
Effective therapy of murine models of human leukemia and lymphoma with radiolabeled anti-CD30 antibody, HeFi-1. Proc Natl Acad Sci U S A (2007) 0.81
One-Year Postapproval Clinical Experience with Radium-223 Dichloride in Patients with Metastatic Castrate-Resistant Prostate Cancer. Cancer Biother Radiopharm (2015) 0.80
Influence of tumour size on the efficacy of targeted alpha therapy with (213)Bi-[DOTA(0),Tyr(3)]-octreotate. EJNMMI Res (2016) 0.80
Novel modular transporters delivering anticancer drugs and foreign DNA to the nuclei of target cancer cells. J BUON (2009) 0.79
Delivery of therapeutic radioisotopes using nanoparticle platforms: potential benefit in systemic radiation therapy. Nanotechnol Sci Appl (2010) 0.78
A method to predict response of cell populations to cocktails of chemotherapeutics and radiopharmaceuticals: validation with daunomycin, doxorubicin, and the alpha particle emitter (210)Po. Nucl Med Biol (2012) 0.77
Preparation and in vivo evaluation of radioiodinated closo-decaborate(2-) derivatives to identify structural components that provide low retention in tissues. Nucl Med Biol (2010) 0.77
Quantitative single-particle digital autoradiography with α-particle emitters for targeted radionuclide therapy using the iQID camera. Med Phys (2015) 0.76
Combining α-Radioimmunotherapy and Adoptive T Cell Therapy to Potentiate Tumor Destruction. PLoS One (2015) 0.76
Myeloablative radioimmunotherapy in conditioning prior to haematological stem cell transplantation: closing the gap between benefit and toxicity? Eur J Nucl Med Mol Imaging (2009) 0.76
Targeted Radionuclide Therapy: An Evolution Toward Precision Cancer Treatment. AJR Am J Roentgenol (2017) 0.75
Stability and in vivo behavior of Rh[16aneS4-diol]211 at complex: a potential precursor for astatine radiopharmaceuticals. Nucl Med Biol (2014) 0.75
Immunohistochemical evaluation of epithelial ovarian carcinomas identifies three different expression patterns of the MX35 antigen, NaPi2b. BMC Cancer (2017) 0.75
Radiopharmaceutical chemistry of targeted radiotherapeutics, part 4: Strategies for (211)At labeling at high activities and radiation doses of (211)At α-particles. Nucl Med Biol (2016) 0.75
Streptavidin in antibody pretargeting. 5. chemical modification of recombinant streptavidin for labeling with the alpha-particle-emitting radionuclides 213Bi and 211At. Bioconjug Chem (2007) 0.75
IL13RA2 targeted alpha particle therapy against glioblastomas. Oncotarget (2017) 0.75
Tumor targeting with antibody-functionalized, radiolabeled carbon nanotubes. J Nucl Med (2007) 3.08
Bone marrow-derived endothelial progenitor cells are a major determinant of nascent tumor neovascularization. Genes Dev (2007) 2.60
Early death rate in acute promyelocytic leukemia remains high despite all-trans retinoic acid. Blood (2011) 2.59
Targeting the intracellular WT1 oncogene product with a therapeutic human antibody. Sci Transl Med (2013) 2.03
(124)I-huA33 antibody PET of colorectal cancer. J Nucl Med (2011) 2.01
Targeted alpha particle immunotherapy for myeloid leukemia. Blood (2002) 1.99
Pentostatin, cyclophosphamide, and rituximab is an active, well-tolerated regimen for patients with previously treated chronic lymphocytic leukemia. J Clin Oncol (2006) 1.98
Vitamin C antagonizes the cytotoxic effects of antineoplastic drugs. Cancer Res (2008) 1.98
Selective killing of tumor neovasculature paradoxically improves chemotherapy delivery to tumors. Cancer Res (2010) 1.80
Administration of ATRA to newly diagnosed patients with acute promyelocytic leukemia is delayed contributing to early hemorrhagic death. Leuk Res (2013) 1.70
Paradoxical glomerular filtration of carbon nanotubes. Proc Natl Acad Sci U S A (2010) 1.54
Synthetic peptide analogs derived from bcr/abl fusion proteins and the induction of heteroclitic human T-cell responses. Haematologica (2005) 1.50
PET imaging of soluble yttrium-86-labeled carbon nanotubes in mice. PLoS One (2007) 1.43
Vaccination with synthetic analog peptides derived from WT1 oncoprotein induces T-cell responses in patients with complete remission from acute myeloid leukemia. Blood (2010) 1.41
Alpha-particle emitting atomic generator (Actinium-225)-labeled trastuzumab (herceptin) targeting of breast cancer spheroids: efficacy versus HER2/neu expression. Clin Cancer Res (2004) 1.38
Self-assembly of carbon nanotubes and antibodies on tumours for targeted amplified delivery. Nat Nanotechnol (2013) 1.35
Targeted actinium-225 in vivo generators for therapy of ovarian cancer. Cancer Res (2003) 1.31
Design and synthesis of 225Ac radioimmunopharmaceuticals. Appl Radiat Isot (2002) 1.26
Peptide epitopes from the Wilms' tumor 1 oncoprotein stimulate CD4+ and CD8+ T cells that recognize and kill human malignant mesothelioma tumor cells. Clin Cancer Res (2007) 1.23
A multivalent DNA aptamer specific for the B-cell receptor on human lymphoma and leukemia. Nucleic Acids Res (2010) 1.22
Human mitochondrial peptide deformylase, a new anticancer target of actinonin-based antibiotics. J Clin Invest (2004) 1.21
Realizing the potential of the Actinium-225 radionuclide generator in targeted alpha particle therapy applications. Adv Drug Deliv Rev (2008) 1.20
WT1 peptide vaccinations induce CD4 and CD8 T cell immune responses in patients with mesothelioma and non-small cell lung cancer. Cancer Immunol Immunother (2010) 1.20
High-throughput identification of inhibitors of human mitochondrial peptide deformylase. J Biomol Screen (2007) 1.18
Sequential cytarabine and alpha-particle immunotherapy with bismuth-213-lintuzumab (HuM195) for acute myeloid leukemia. Clin Cancer Res (2010) 1.17
Imaging and treating tumor vasculature with targeted radiolabeled carbon nanotubes. Int J Nanomedicine (2010) 1.12
Familial Alzheimer disease presenilin-1 mutations alter the active site conformation of γ-secretase. J Biol Chem (2012) 1.10
Synthesis and biodistribution of oligonucleotide-functionalized, tumor-targetable carbon nanotubes. Nano Lett (2008) 1.09
Selective alpha-particle mediated depletion of tumor vasculature with vascular normalization. PLoS One (2007) 1.08
A new human peptide deformylase inhibitable by actinonin. Biochem Biophys Res Commun (2003) 1.07
A multivalent bcr-abl fusion peptide vaccination trial in patients with chronic myeloid leukemia. Blood (2003) 1.07
Efforts to control the errant products of a targeted in vivo generator. Cancer Res (2005) 1.06
Pharmacokinetics, dosimetry, and toxicity of the targetable atomic generator, 225Ac-HuM195, in nonhuman primates. J Nucl Med (2004) 1.06
Renal tubulointerstitial changes after internal irradiation with alpha-particle-emitting actinium daughters. J Am Soc Nephrol (2005) 1.05
Single-walled carbon nanotubes deliver peptide antigen into dendritic cells and enhance IgG responses to tumor-associated antigens. ACS Nano (2011) 1.04
Refractory Aspergillus pneumonia in patients with acute leukemia: successful therapy with combination caspofungin and liposomal amphotericin. Cancer (2003) 1.02
Mitigation of radiation nephropathy after internal alpha-particle irradiation of kidneys. Int J Radiat Oncol Biol Phys (2006) 1.02
Pentostatin and cyclophosphamide: an effective new regimen in previously treated patients with chronic lymphocytic leukemia. J Clin Oncol (2003) 0.99
Inhibition of neovascularization to simultaneously ameliorate graft-vs-host disease and decrease tumor growth. J Natl Cancer Inst (2010) 0.98
Engineered liposomes for potential alpha-particle therapy of metastatic cancer. J Nucl Med (2004) 0.97
Targeted deletion of T-cell clones using alpha-emitting suicide MHC tetramers. Blood (2004) 0.95
A high-throughput screen for alpha particle radiation protectants. Assay Drug Dev Technol (2010) 0.95
Will nanotechnology influence targeted cancer therapy? Semin Radiat Oncol (2011) 0.95
Complete remissions observed in acute myeloid leukemia following prolonged exposure to lintuzumab: a phase 1 trial. Leuk Lymphoma (2009) 0.94
Peptide binding motif predictive algorithms correspond with experimental binding of leukemia vaccine candidate peptides to HLA-A*0201 molecules. Leuk Res (2006) 0.94
Synthetic tumor-specific breakpoint peptide vaccine in patients with chronic myeloid leukemia and minimal residual disease: a phase 2 trial. Cancer (2009) 0.93
Targeted nanomaterials for radiotherapy. Nanomedicine (Lond) (2007) 0.92
Inhibition of human peptide deformylase disrupts mitochondrial function. Mol Cell Biol (2010) 0.91
Structure and activity of human mitochondrial peptide deformylase, a novel cancer target. J Mol Biol (2009) 0.91
Alpha particles induce apoptosis through the sphingomyelin pathway. Radiat Res (2011) 0.91
Improved tumor imaging and therapy via i.v. IgG-mediated time-sequential modulation of neonatal Fc receptor. J Clin Invest (2007) 0.90
Treatment of neuroblastoma meningeal carcinomatosis with intrathecal application of alpha-emitting atomic nanogenerators targeting disialo-ganglioside GD2. Clin Cancer Res (2004) 0.89
A high-throughput scintillation proximity-based assay for human DNA ligase IV. Assay Drug Dev Technol (2011) 0.88
Identification of a human cyclin D1-derived peptide that induces human cytotoxic CD4 T cells. PLoS One (2009) 0.88
Randomized phase IIb study of low-dose cytarabine and lintuzumab versus low-dose cytarabine and placebo in older adults with untreated acute myeloid leukemia. Haematologica (2012) 0.87
Toward a prostate specific antigen-based prostate cancer diagnostic assay: preparation of keyhole limpet hemocyanin-conjugated normal and transformed prostate specific antigen fragments. J Am Chem Soc (2008) 0.87
Radioimmunotherapy for acute leukemia. Cancer Control (2002) 0.86
Non-natural and photo-reactive amino acids as biochemical probes of immune function. PLoS One (2008) 0.85
Mechanisms of resistance to high and low linear energy transfer radiation in myeloid leukemia cells. Blood (2012) 0.85
Enhanced retention of the alpha-particle-emitting daughters of Actinium-225 by liposome carriers. Bioconjug Chem (2007) 0.85
Histone deacetylase inhibition improves dendritic cell differentiation of leukemic blasts with AML1-containing fusion proteins. J Leukoc Biol (2004) 0.84
A self-assembling short oligonucleotide duplex suitable for pretargeting. Nucleic Acid Ther (2013) 0.84
Influence of the linker on the biodistribution and catabolism of actinium-225 self-immolative tumor-targeted isotope generators. Bioconjug Chem (2006) 0.83
Immunotoxin resistance in multidrug resistant cells. Cancer Res (2003) 0.83
Deploying RNA and DNA with Functionalized Carbon Nanotubes. J Phys Chem C Nanomater Interfaces (2013) 0.83
Immunotherapeutic approaches for hematologic malignancies. Hematology Am Soc Hematol Educ Program (2004) 0.83
Novel targeted and immunotherapeutic strategies in chronic myeloid leukemia. Semin Hematol (2003) 0.82
Natural killer cells license dendritic cell cross-presentation of B lymphoma cell--associated antigens. Clin Cancer Res (2005) 0.81
Vaccination with CD20 peptides induces a biologically active, specific immune response in mice. Blood (2002) 0.81
Approaching untargetable tumor-associated antigens with antibodies. Oncoimmunology (2013) 0.80
Bone marrow purging studies in acute myelogenous leukemia using the recombinant anti-CD33 immunotoxin HuM195/rGel. Biol Blood Marrow Transplant (2003) 0.80
CD8+ T-cell-dependent immunity following xenogeneic DNA immunization against CD20 in a tumor challenge model of B-cell lymphoma. Clin Cancer Res (2005) 0.80
Remodeling specific immunity by use of MHC tetramers: demonstration in a graft-versus-host disease model. Blood (2005) 0.79
Peptide vaccines for myeloid leukaemias. Best Pract Res Clin Haematol (2008) 0.79
Dysregulation of IRP1-mediated iron metabolism causes gamma ray-specific radioresistance in leukemia cells. PLoS One (2012) 0.79
Identification of benzofuran-4,5-diones as novel and selective non-hydroxamic acid, non-peptidomimetic based inhibitors of human peptide deformylase. Bioorg Med Chem Lett (2011) 0.79
Therapeutic antibodies to intracellular targets in cancer therapy. Expert Opin Biol Ther (2013) 0.79
Large anti-HER2/neu liposomes for potential targeted intraperitoneal therapy of micrometastatic cancer. J Liposome Res (2010) 0.78
Emerging new approaches for the treatment of acute promyelocytic leukemia. Ther Adv Hematol (2011) 0.78
Induction and postremission strategies in acute myeloid leukemia: state of the art and future directions. Hematol Oncol Clin North Am (2011) 0.78
A single, high dose of idarubicin combined with cytarabine as induction therapy for adult patients with recurrent or refractory acute lymphoblastic leukemia. Cancer (2002) 0.77
Antibody-based treatment of acute myeloid leukaemia. Expert Opin Biol Ther (2004) 0.77
Antibody-drug conjugates in acute myeloid leukemia. Nat Clin Pract Oncol (2006) 0.75
Reaching un-drugable intracellular targets with the long arm of antibodies. Oncotarget (2013) 0.75
Immunoreactivity assay for alpha-particle emitting monoclonal antibody constructs. Appl Radiat Isot (2005) 0.75
A therapeutic T cell receptor mimic antibody targets tumor-associated PRAME peptide/HLA-I antigens. J Clin Invest (2017) 0.75
Antibody therapy in acute myeloid leukemia: current status and future directions. Clin Lymphoma (2002) 0.75
Meeting report: drug carriers in medicine and biology. Mol Pharm (2009) 0.75
Radioimmunotherapy of leukemia. Adv Pharmacol (2004) 0.75
Immune therapy of chronic myelogenous leukemia. Leuk Res (2005) 0.75